TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00885313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA250
Description: DHA 250 mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA500
Description: DHA 500 mg/kg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
Study: NCT04621435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 labelled (68Ga-) FAP-2286
Description: The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 labelled (68Ga-) FAP-2286
Description: The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 labelled (68Ga-) FAP-2286
Description: The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) imaging
Description: Participants will be scanned for approximately 30 to 45 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) imaging
Description: Participants will be scanned for approximately 30 to 45 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) imaging
Description: Participants will be scanned for approximately 30 to 45 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) imaging
Description: Participants will be scanned for approximately 30 to 45 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled (64Cu-) FAP-2286
Description: The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled (64Cu-) FAP-2286
Description: The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled (64Cu-) FAP-2286
Description: The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
Study: NCT00819546

Intervention type: DRUG
Group type: OTHER
Intervention: RAD001
Description: Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.

Intervention type: DRUG
Group type: OTHER
Intervention: PKC412
Description: 50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
Study: NCT03910855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
Study: NCT03178149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7317
Description: subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7317
Description: subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study: NCT03777878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: 20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: 20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
Study: NCT03178149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: oral
Study: NCT00368745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
Study: NCT01147887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug combination/ 26489112
Description: On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
Study: NCT04204694

Intervention type: OTHER
Intervention: 3-time blood sampling for septic shock patients
Description: 15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock

Intervention type: OTHER
Intervention: Only one blood sampling for controls patients
Description: 15 mL blood are sampled from a blood donation
Study: NCT03178149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: oral
Study: NCT04310982

Intervention type: DEVICE
Intervention: The G-Walk sensor system (G-Walk)
Description: The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
Study: NCT03294460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (Oral)
Description: Oral Self-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (IV)
Description: IV Self-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (Ethanol)
Description: IV and Oral Self-administration
Study: NCT04444921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03777878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 2 ampoules of TA in 100 ml saline by slow infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to carbetocin
Description: placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to carbetocin
Description: placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Study: NCT03171519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
Study: NCT03811392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernioraphy/Caudal block
Description: 30 patients will receive a caudal block after induction of general anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernioraphy/Quadratus Lumborum block
Description: 30 patients will receive ultrasound guided quadrates lumborum block
Study: NCT02841683

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tabac Info Service
Description: A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
Study: NCT02063867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Decolonization
Description: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Study: NCT01285570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Intravenously (IV)
Description: 480 microg/kg daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Intravenously (IV)
Description: 160 microg/kg daily (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: Placebo
Study: NCT00802126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy IVB + rf-PDT
Description: low-fluence photodynamic therapy combined with intravitreal bevacizumab
Study: NCT00093496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study: NCT00402428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin interferon alfa-2b
Description: 900 mcg or 1200mcg every two week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin interferon alfa-2b
Description: 900 mcg or 1200mcg every two week for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a
Description: 180 mcg once a week for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)
Study: NCT04666103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative thermal ablation
Description: After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy.
Study: NCT02975739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 (poly L lactic acid) microspheres
Description: Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
Study: NCT01487174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD019
Description: KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
Study: NCT00402428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)
Study: NCT03576196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Pain Neuroscience Education
Description: Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
Study: NCT02358161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and nab paclitaxel
Description: DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
Study: NCT02132455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
Study: NCT03241680

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Search of anal citology alterations
Description: All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE).
Study: NCT02818023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
Study: NCT03938766

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA PET/CT
Description: Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
Study: NCT02021617

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Intraosseous access
Description: The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
Study: NCT00361868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate (F) + metformin (M) hydrochloride fixed combination
Description: First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
Study: NCT04251299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based, mentored vegetable gardening program
Description: The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
Study: NCT00615225

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
Study: NCT03777878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to oxytocin
Description: two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
Study: NCT03075696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
Study: NCT02132455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
Study: NCT00975585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: soft contact lens, 2-week replacement indicated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: soft contact lens with a 4-week replacement indicated.
Study: NCT02526576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal Vasular Fraction
Description: The stromal vascular fraction obtained from adipose tissue will be added to the graft
Study: NCT03023579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The star excursion balance test
Study: NCT04925076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A beverage that does not meaningfully increase breath alcohol concentration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A beverage that does not meaningfully increase breath alcohol concentration.
Study: NCT01905345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training
Study: NCT03086707

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.